Saelens X - Search Results

1

Single-domain antibodies make a difference.

Saelens X, Schepens B. Saelens X, et al. Science. 2021 Feb 12;371(6530):681-682. doi: 10.1126/science.abg2294. Science. 2021. PMID: 33574203 No abstract available.

2

M2e-based universal influenza A vaccine.

Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. Fiers W, et al. Among authors: saelens x. Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Vaccine. 2009. PMID: 19840661 Review.

3

Identification of polymorphisms in the ovine Shadow of prion protein (SPRN) gene and assessment of their effect on promoter activity and susceptibility for classical scrapie.

Lampo E, Duchateau L, Schepens B, Van Poucke M, Saelens X, Erkens T, Van Zeveren A, Peelman LJ. Lampo E, et al. Among authors: saelens x. Anim Genet. 2010 Apr;41(2):169-78. doi: 10.1111/j.1365-2052.2009.01984.x. Epub 2009 Nov 16. Anim Genet. 2010. PMID: 19917049

4

Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective.

De Filette M, Ysenbaert T, Roose K, Schotsaert M, Roels S, Goossens E, Schepens B, Fiers W, Saelens X. De Filette M, et al. Among authors: saelens x. J Gen Virol. 2011 Feb;92(Pt 2):301-6. doi: 10.1099/vir.0.027086-0. Epub 2010 Oct 21. J Gen Virol. 2011. PMID: 20965983

5

Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection.

Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X. Ibañez LI, et al. Among authors: saelens x. J Infect Dis. 2011 Apr 15;203(8):1063-72. doi: 10.1093/infdis/jiq168. J Infect Dis. 2011. PMID: 21450996

6

Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ. Hultberg A, et al. Among authors: saelens x. PLoS One. 2011 Apr 1;6(4):e17665. doi: 10.1371/journal.pone.0017665. PLoS One. 2011. PMID: 21483777 Free PMC article.

7

Nanobodies®: new ammunition to battle viruses.

Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X. Vanlandschoot P, et al. Among authors: saelens x. Antiviral Res. 2011 Dec;92(3):389-407. doi: 10.1016/j.antiviral.2011.09.002. Epub 2011 Sep 10. Antiviral Res. 2011. PMID: 21939690 Review.

8

Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.

Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W, Vanlandschoot P, Saelens X. Schepens B, et al. Among authors: saelens x. J Infect Dis. 2011 Dec 1;204(11):1692-701. doi: 10.1093/infdis/jir622. Epub 2011 Oct 12. J Infect Dis. 2011. PMID: 21998474

9

Natural and long-lasting cellular immune responses against influenza in the M2e-immune host.

Schotsaert M, Ysenbaert T, Neyt K, Ibañez LI, Bogaert P, Schepens B, Lambrecht BN, Fiers W, Saelens X. Schotsaert M, et al. Among authors: saelens x. Mucosal Immunol. 2013 Mar;6(2):276-87. doi: 10.1038/mi.2012.69. Epub 2012 Jul 18. Mucosal Immunol. 2013. PMID: 22806098 Free article.

10

Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly.

Verhelst J, Parthoens E, Schepens B, Fiers W, Saelens X. Verhelst J, et al. Among authors: saelens x. J Virol. 2012 Dec;86(24):13445-55. doi: 10.1128/JVI.01682-12. Epub 2012 Sep 26. J Virol. 2012. PMID: 23015724 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

195 results

Search Page